Książek Ignacy, Ligęza Artur, Drzymała Franciszek, Borek Adam, Miszczyk Marcin, Francuz Marcin Radosław, Matsukawa Akihiro, Yanagisawa Takafumi, Fazekas Tamás, Zapała Łukasz, Rajwa Paweł
Department of Urology, Medical University of Silesia, 41-800 Zabrze, Poland.
Department of Urology, Medical University of Vienna, 1090 Vienna, Austria.
Cancers (Basel). 2024 Jul 1;16(13):2433. doi: 10.3390/cancers16132433.
Theranostics utilize ligands that chelate radionuclides and selectively bind with cancer-specific membrane antigens. In the case of prostate cancer (PCa), the state-of-the-art lutetium-177-PSMA combines the radioactive β-emitter Lu with Vipivotide Tetraxetan, a prostate-specific membrane antigen (PSMA)-binding ligand. Several studies have been conducted, and the therapy is not without adverse effects (e.g., xerostomia, nausea, and fatigue); however, few events are reported as severe. The available evidence supports the use of Lu-PSMA in selected metastatic castration-resistant prostate cancer patients, and the treatment is considered a standard of care in several clinical scenarios. Emerging research shows promising results in the setting of hormone-sensitive prostate cancer; however, evidence from high-quality controlled trials is still missing. In this review, we discuss the available evidence for the application of Lu-PSMA in the management of PCa patients.
治疗诊断学利用能螯合放射性核素并与癌症特异性膜抗原选择性结合的配体。就前列腺癌（PCa）而言，目前最先进的镥-177-PSMA将放射性β发射体镥与维普肽四乙酸（一种前列腺特异性膜抗原（PSMA）结合配体）相结合。已经开展了多项研究，这种疗法并非没有副作用（例如口干、恶心和疲劳）；然而，很少有严重不良反应的报告。现有证据支持在选定的转移性去势抵抗性前列腺癌患者中使用镥-PSMA，并且在几种临床情况下该治疗被视为标准治疗方法。新兴研究在激素敏感性前列腺癌的治疗中显示出有前景的结果；然而，高质量对照试验的证据仍然缺失。在本综述中，我们讨论了镥-PSMA在前列腺癌患者管理中应用的现有证据。
